ARCHIVES

Amgen Claimed QOL Benefit Despite FDA Label Change.

This article is from The Cancer Letter archive.

Vol. 33 No. 19 | May 18, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: Mauer to Leave St. Jude For U. Tennessee As Cancer Program Director; Harvard, MIT Share ACS Award

July 29, 1983

California approves $3 billion program for stem-cell research.

November 5, 2004

NCCS Networker Volume 8 Issue 4, Winter 1994

January 13, 1994

In Brief: FDA’s Burlington Moves to Wyeth-Ayerst; NAS Award to Beckman; Genetics Online

February 5, 1999

HEW To Pay All Care Cost At 26 Hospices

January 11, 1980

In Brief: Terms Expire Next Year For Six NCAB Members, One On Panel; Fraumeni Preventative Oncology President

October 16, 1981